Clinical information: (b)(6).It was reported that on (b)(6) 2023, a 17mm sjm regent heart valve with flex cuff was successfully implanted in a patient.It was noted that on (b)(6) 2023, the patient was admitted to the hospital for treatment of persistent atrial fibrillation, that worsened since implant of the 17mm sjm regent heart valve with flex cuff.An electrocardiogram was performed and revealed atrial flutter and t-wave changes.The patient was also noticeably weaker and lost weight.On (b)(6) 2023, the patient was administered diltiazem.On (b)(6) 2023, the patient was administered alprostadil.It was also noted that the patient had also been administered anti-coagulants and gastric protection.On (b)(6) 2023, the decision was made to perform a catheter radiofrequency ablation.On (b)(6) 2023, the patient was discharged.The patient's atrial flutter, t-wave changes and worsening atrial fibrillation are attributed to the patient's primary rheumatic heart disease and past medical history.There is no allegation of malfunction against the abbott device or procedure.
|
An event of worsening atrial fibrillation, atrial flutter and t-wave changes after almost 6 months of implant was reported.A returned device assessment could not be performed as the device remains implanted and was not returned for analysis.The device history record was reviewed to ensure that each manufacturing and inspection operation was performed and the product met all specifications.Based on the information received, the cause of the reported incident could not be conclusively determined, however information from field indicated that reported event was attributed to the patient's primary rheumatic heart disease and past medical history.There is no indication of a product quality issue with respect to labeling design or manufacturing of the device.
|